New targeted therapies for mutations in EGFR, ALK (anaplastic lymphoma kinase), immunotherapy PD-1 (programmed death-1) receptor, and programmed death ligand 1 (PDL-1) have shown promising results in both primary tumor and BM but require further studies. This evidence concerns the gene CD274 and neoplasm.